Andromeda Capital’s AbbVie ABBV Stock Holding History

Andromeda Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-246,600	Closed	-$14.2M	–	25
2014 Q3	$14.2M	Buy	+246,600	New	+$13.7M	0.84%	32

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Andromeda Capital's ABBV Position: Q4 2014 in Review

Andromeda Capital sold out of AbbVie (ABBV) in Q4 2014, closing a stake of 59,104 shares — an estimated $3.41M sold.

Andromeda Capital first reported a position in ABBV in Q3 2014 and held it in 1 quarter. The position peaked at $3.41M in Q3 2014. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q4 2014.

Andromeda Capital reported no remaining AbbVie position as of Q4 2014 after selling out during the quarter.
Andromeda Capital sold 59,104 AbbVie shares in Q4 2014, an estimated $3.41M.
Andromeda Capital first reported a position in AbbVie in Q3 2014 and held it in 1 quarter.
Andromeda Capital's AbbVie position peaked at $3.41M in Q3 2014.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q4 2014.

Based on Andromeda Capital's 13F filing for Q4 2014, filed 17 Feb 2015.